These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 9258743)

  • 1. Bisphosphonate effects and the bone remodeling transient.
    Heaney RP; Yates AJ; Santora AC
    J Bone Miner Res; 1997 Aug; 12(8):1143-51. PubMed ID: 9258743
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of alendronate on bone quality and remodeling in glucocorticoid-induced osteoporosis: a histomorphometric analysis of transiliac biopsies.
    Chavassieux PM; Arlot ME; Roux JP; Portero N; Daifotis A; Yates AJ; Hamdy NA; Malice MP; Freedholm D; Meunier PJ
    J Bone Miner Res; 2000 Apr; 15(4):754-62. PubMed ID: 10780867
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension.
    Ensrud KE; Barrett-Connor EL; Schwartz A; Santora AC; Bauer DC; Suryawanshi S; Feldstein A; Haskell WL; Hochberg MC; Torner JC; Lombardi A; Black DM;
    J Bone Miner Res; 2004 Aug; 19(8):1259-69. PubMed ID: 15231012
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The bone-remodeling transient: implications for the interpretation of clinical studies of bone mass change.
    Heaney RP
    J Bone Miner Res; 1994 Oct; 9(10):1515-23. PubMed ID: 7817796
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bone remodeling at the iliac crest can predict the changes in remodeling dynamics, microdamage accumulation, and mechanical properties in the lumbar vertebrae of dogs.
    Mashiba T; Hui S; Turner CH; Mori S; Johnston CC; Burr DB
    Calcif Tissue Int; 2005 Sep; 77(3):180-5. PubMed ID: 16265598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early changes in urinary cross-linked N-terminal telopeptides of type I collagen level correlate with 1-year response of lumbar bone mineral density to alendronate in postmenopausal Japanese women with osteoporosis.
    Iwamoto J; Takeda T; Sato Y; Uzawa M
    J Bone Miner Metab; 2005; 23(3):238-42. PubMed ID: 15838627
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial.
    Greenspan SL; Parker RA; Ferguson L; Rosen HN; Maitland-Ramsey L; Karpf DB
    J Bone Miner Res; 1998 Sep; 13(9):1431-8. PubMed ID: 9738515
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The basis for the post-parathyroidectomy increase in bone mass.
    Heaney RP
    J Bone Miner Res; 2002 Nov; 17 Suppl 2():N154-7. PubMed ID: 12412794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two-year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta.
    DiMeglio LA; Peacock M
    J Bone Miner Res; 2006 Jan; 21(1):132-40. PubMed ID: 16355282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of risedronate on canine cancellous bone remodeling: three-dimensional kinetic reconstruction of the remodeling site.
    Boyce RW; Paddock CL; Gleason JR; Sletsema WK; Eriksen EF
    J Bone Miner Res; 1995 Feb; 10(2):211-21. PubMed ID: 7754801
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis.
    Gallagher JC; Rosen CJ; Chen P; Misurski DA; Marcus R
    Bone; 2006 Dec; 39(6):1268-75. PubMed ID: 16884968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term predictions of the therapeutic equivalence of daily and less than daily alendronate dosing.
    Hernandez CJ; Beaupré GS; Marcus R; Carter DR
    J Bone Miner Res; 2002 Sep; 17(9):1662-6. PubMed ID: 12211437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alendronate prevents further bone loss in renal transplant recipients.
    Giannini S; D'Angelo A; Carraro G; Nobile M; Rigotti P; Bonfante L; Marchini F; Zaninotto M; Dalle Carbonare L; Sartori L; Crepaldi G
    J Bone Miner Res; 2001 Nov; 16(11):2111-7. PubMed ID: 11697808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vertebral endplate morphology follows bone remodeling principles.
    Grosland NM; Goel VK
    Spine (Phila Pa 1976); 2007 Nov; 32(23):E667-73. PubMed ID: 17978642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alendronate improves bone mineral density in primary biliary cirrhosis: a randomized placebo-controlled trial.
    Zein CO; Jorgensen RA; Clarke B; Wenger DE; Keach JC; Angulo P; Lindor KD
    Hepatology; 2005 Oct; 42(4):762-71. PubMed ID: 16175618
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alendronate prevents loss of bone density associated with discontinuation of hormone replacement therapy: a randomized controlled trial.
    Ascott-Evans BH; Guanabens N; Kivinen S; Stuckey BG; Magaril CH; Vandormael K; Stych B; Melton ME
    Arch Intern Med; 2003 Apr; 163(7):789-94. PubMed ID: 12695269
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Once-weekly oral alendronate 70 mg in patients with glucocorticoid-induced bone loss: a 12-month randomized, placebo-controlled clinical trial.
    Stoch SA; Saag KG; Greenwald M; Sebba AI; Cohen S; Verbruggen N; Giezek H; West J; Schnitzer TJ
    J Rheumatol; 2009 Aug; 36(8):1705-14. PubMed ID: 19487264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Simulation through the method of finite element of alendronate in a model of bone remodeling based on damage mechanics].
    Zeman ME; García JM; Doblaré M
    Acta Cient Venez; 2003; 54(1):36-42. PubMed ID: 14515765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of simvastatin on bone turnover and BMD: a 1-year randomized controlled trial in postmenopausal osteopenic women.
    Rejnmark L; Buus NH; Vestergaard P; Heickendorff L; Andreasen F; Larsen ML; Mosekilde L
    J Bone Miner Res; 2004 May; 19(5):737-44. PubMed ID: 15068496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alterations in canine vertebral bone turnover, microdamage accumulation, and biomechanical properties following 1-year treatment with clinical treatment doses of risedronate or alendronate.
    Allen MR; Iwata K; Phipps R; Burr DB
    Bone; 2006 Oct; 39(4):872-9. PubMed ID: 16765660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.